Press Releases

GlobeNewswire, Inc.

IRVINE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the...

GlobeNewswire, Inc.

Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy...

GlobeNewswire, Inc.

Rice herbicide-tolerance traits performed well in Latin American field trials and are now being tested by customer Interoc in its own varieties Initiated the manufacturing process for initial two biofragrance products; biofragrance program...

GlobeNewswire, Inc.

Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth Jemperli approved in the U.S. as the first and only immunotherapy for adults with stage II and III...

GlobeNewswire, Inc.

The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer.

GlobeNewswire, Inc.

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the...

GlobeNewswire, Inc.

KUALA LUMPUR, MALAYSIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today...

GlobeNewswire, Inc.

Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the first half of 2027 LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Azora...

GlobeNewswire, Inc.

REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Planned FDA De Novo submission in late Q4...

GlobeNewswire, Inc.

-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Received FDA clearance of...

GlobeNewswire, Inc.

NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance Long-term extension NDV-01 Phase 2 data demonstrate continued durability of response: 86% of 12-month...

GlobeNewswire, Inc.

Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus Initiated Phase 2 studies with PRA-216, a half-life-extended...

GlobeNewswire, Inc.

On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up from 470, driven by...

GlobeNewswire, Inc.

Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan facility with Trinity Capital;...

GlobeNewswire, Inc.

– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 – – Advanced three Phase 2 clinical trials for...

GlobeNewswire, Inc.

ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001...

GlobeNewswire, Inc.

– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and...

GlobeNewswire, Inc.

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership...

GlobeNewswire, Inc.

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20...

GlobeNewswire, Inc.

- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML;...